<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01336803</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-20253(osteosarcoma)</org_study_id>
    <secondary_id>SU-04062011-7666</secondary_id>
    <secondary_id>PEDSBONE0006</secondary_id>
    <nct_id>NCT01336803</nct_id>
  </id_info>
  <brief_title>Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI</brief_title>
  <acronym>Osteosarcoma</acronym>
  <official_title>Pilot Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heike E Daldrup-Link</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot trial studies the differentiation of bone sarcomas and osteomyelitis with
      ferumoxytol-enhanced magnetic resonance imaging (MRI). Imaging procedures that allow doctors
      to more accurately differentiate between malignant bone sarcomas and osteomyelitis may help
      in diagnosing patients correctly and may result in more timely treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND; In this study, T1, T2, and T2* represent parameters of magnetic resonance imaging
      (MRI).

      The T1 relaxation time, also known as the spin-lattice relaxation time, is a measure of how
      quickly the net magnetization vector (NMV) recovers to its ground state in the direction of
      B0. T1 is assessed immediately post-contrast. A T1-weighted image (T1WI ) is one of the basic
      pulse sequences in MRI and demonstrates differences in the T1 relaxation times of tissues. A
      T1WI relies upon the longitudinal relaxation of a tissue's net magnetization vector (NMV).

      T2 is a time constant for the decay of transverse magnetization arising from natural
      interactions at the atomic or molecular levels, and be considered the &quot;natural&quot; or &quot;true&quot; T2
      of the tissue. However, in any nuclear magnetic resonance (NMR) experiment, transverse
      magnetization decays much faster than would be predicted by natural atomic and molecular
      mechanisms. Accordingly, T2 * is the time constant for the decay of transverse magnetization
      as observed in a tissue during a MRI scan, and be considered the&quot;effective T2&quot; (represented
      as T2*). T2* is always â‰¤ T2. In this study, T2 * is assessed after 24 hours.

      OUTLINE:

      Patients receive ferumoxytol intravenously (IV) and then undergo ferumoxytol-enhanced MRI up
      to 1 hour after infusion and up to 24 hours post-infusion.

      PRIMARY OBJECTIVES:

        -  Establish magnetic resonance (MR) imaging characteristics of bone sarcomas and
           osteomyelitis based on their ferumoxytol-enhancement on relatively early post-contrast
           T1-weighted images.

        -  Establish MR imaging characteristics of bone sarcomas and osteomyelitis based on their
           ferumoxytol-enhancement on delayed postcontrast T2-weighted images.

        -  Establish T2-weighted MR imaging characteristics of iron-labeled mesenchymal stem cell
           (MSC) in osteonecrotic bone over time, before and after surgical core decompression and
           bone marrow implantation.

        -  Adding a second branch for patients who can not receive ferumoxytol but still getting
           the MRI exam.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2011</start_date>
  <completion_date type="Actual">October 2018</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>T2* Relaxation Time of Bone Sarcomas and Osteomyelitis Subjects</measure>
    <time_frame>24 hours</time_frame>
    <description>Differentiation of bone sarcomas and osteomyelitis with ferumoxytol-enhanced magnetic resonance imaging (MRI) was assessed as the difference of mean T2 * relaxation time of bone sarcoma and osteomyelitis subjects. The outcome is reported as the difference of the mean T2 * values, with standard deviation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Differentiation of Bone Sarcomas Pre-ferumoxytol and Post-ferumoxytol Contrast</measure>
    <time_frame>Baseline and Post-Treatment-24 hours</time_frame>
    <description>Differentiation of bone sarcomas pre-ferumoxytol and post-ferumoxytol contrast was assessed by difference of mean T2 * relaxation time pre-ferumoxytol and post-ferumoxytol contrast, in bone sarcoma subjects only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differentiation of Lymphoma and Bone Sarcomas With Ferumoxytol-enhanced MRI</measure>
    <time_frame>24 hours</time_frame>
    <description>Differentiation of lymphoma from bone sarcoma was assessed as the difference of mean T2 * relaxation time determined by ferumoxytol-enhanced MRI.
.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differentiation of CD68-positive Tumor-associated Macrophages (TAM) in Lymphomas and Bone Sarcomas</measure>
    <time_frame>24 hours</time_frame>
    <description>Differentiation of CD68-positive tumor-associated macrophages (TAM) between lymphoma and bone sarcoma was assessed as the difference of mean area density of CD68-positive TAM in those populations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differentiation of CD163-positive Tumor-associated Macrophages (TAM) in Lymphomas and Bone Sarcomas</measure>
    <time_frame>24 hours</time_frame>
    <description>Differentiation of CD163-positive tumor-associated macrophages (TAM) between lymphoma and bone sarcoma was assessed as the difference of mean area density of CD163-positive TAM in those populations.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Bone Cancer</condition>
  <condition>Chondrosarcoma</condition>
  <condition>Ewing's Sarcoma</condition>
  <condition>Osteosarcoma</condition>
  <condition>Rhabdomyosarcoma</condition>
  <condition>Bone Necrosis</condition>
  <condition>Bone Sarcoma</condition>
  <condition>Osteomyelitis</condition>
  <arm_group>
    <arm_group_label>Feraheme</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous injection of Feraheme, 5 mg Fe/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Feraheme</intervention_name>
    <description>5 mg/kg by intravenous (IV) administration</description>
    <arm_group_label>Feraheme</arm_group_label>
    <other_name>ferumoxytol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Magnetic Resonance Imaging (MRI) scan</intervention_name>
    <description>Standard of Care magnetic resonance imaging (MRI) scans using GE 1.5T and 3T MRI scanners/</description>
    <arm_group_label>Feraheme</arm_group_label>
    <other_name>Magnetic Resonance (MR) scan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA

          -  Age 10 to 21 years

          -  Suspected or confirmed diagnosis of a bone sarcoma or osteomyelitis

          -  Informed consent with assent as appropriate.

        EXCLUSION CRITERIA

          -  Contraindication to MRI

          -  Presence of metal implants

          -  Need for sedation or anesthesia

          -  Claustrophobia

          -  Hemosiderosis or hemochromatosis

          -  History of allergic reactions to similar compounds will be obtained and patients with
             positive history of allergic reactions will be excluded from the study

          -  Females who are pregnancy or nursing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heike E Daldrup-Link, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Neyssa Marina, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>April 12, 2011</study_first_submitted>
  <study_first_submitted_qc>April 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2011</study_first_posted>
  <results_first_submitted>May 3, 2019</results_first_submitted>
  <results_first_submitted_qc>May 30, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 18, 2019</results_first_posted>
  <last_update_submitted>May 30, 2019</last_update_submitted>
  <last_update_submitted_qc>May 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Heike E Daldrup-Link</investigator_full_name>
    <investigator_title>Professor of Radiology (General Radiology)</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteomyelitis</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Osteosarcoma</mesh_term>
    <mesh_term>Rhabdomyosarcoma</mesh_term>
    <mesh_term>Sarcoma, Ewing</mesh_term>
    <mesh_term>Chondrosarcoma</mesh_term>
    <mesh_term>Bone Neoplasms</mesh_term>
    <mesh_term>Osteonecrosis</mesh_term>
    <mesh_term>Necrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ferrosoferric Oxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 4, 2011</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT01336803/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Feraheme</title>
          <description>Intravenous injection of Feraheme, 5 mg Fe/kg
Feraheme: 5 mg Fe/kg by intravenous adminstration
MR Scan: Standard of Care</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Bone Sarcoma</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Osteomyelitis</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Lymphoma</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Feraheme</title>
          <description>Intravenous injection of Feraheme, 5 mg Fe/kg
Feraheme: 5 mg Fe/kg by intravenous adminstration
MR Scan: Standard of Care</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.7" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>T2* Relaxation Time of Bone Sarcomas and Osteomyelitis Subjects</title>
        <description>Differentiation of bone sarcomas and osteomyelitis with ferumoxytol-enhanced magnetic resonance imaging (MRI) was assessed as the difference of mean T2 * relaxation time of bone sarcoma and osteomyelitis subjects. The outcome is reported as the difference of the mean T2 * values, with standard deviation.</description>
        <time_frame>24 hours</time_frame>
        <population>This initial phase of the study was a pilot assessment of participants with bone sarcomas compared to participants with osteomyelitis.</population>
        <group_list>
          <group group_id="O1">
            <title>Bone Sarcomas</title>
            <description>Participants with bone sarcomas (osteosarcomas and Ewing sarcomas) evaluated with ferumoxytol-enhanced MRI.</description>
          </group>
          <group group_id="O2">
            <title>Osteomyelitis</title>
            <description>Participants with osteomyelitis evaluated with MRI with ferumoxytol enhancement.</description>
          </group>
        </group_list>
        <measure>
          <title>T2* Relaxation Time of Bone Sarcomas and Osteomyelitis Subjects</title>
          <description>Differentiation of bone sarcomas and osteomyelitis with ferumoxytol-enhanced magnetic resonance imaging (MRI) was assessed as the difference of mean T2 * relaxation time of bone sarcoma and osteomyelitis subjects. The outcome is reported as the difference of the mean T2 * values, with standard deviation.</description>
          <population>This initial phase of the study was a pilot assessment of participants with bone sarcomas compared to participants with osteomyelitis.</population>
          <units>milliseconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" spread="1.9"/>
                    <measurement group_id="O2" value="7.7" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Differentiation of Bone Sarcomas Pre-ferumoxytol and Post-ferumoxytol Contrast</title>
        <description>Differentiation of bone sarcomas pre-ferumoxytol and post-ferumoxytol contrast was assessed by difference of mean T2 * relaxation time pre-ferumoxytol and post-ferumoxytol contrast, in bone sarcoma subjects only.</description>
        <time_frame>Baseline and Post-Treatment-24 hours</time_frame>
        <population>Only the participants with bone sarcomas were evaluated for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Bone Sarcomas Pre-ferumoxytol &amp; Post-ferumoxytol Contrast</title>
            <description>Participants with bone sarcomas (osteosarcomas and Ewing sarcomas) only.</description>
          </group>
        </group_list>
        <measure>
          <title>Differentiation of Bone Sarcomas Pre-ferumoxytol and Post-ferumoxytol Contrast</title>
          <description>Differentiation of bone sarcomas pre-ferumoxytol and post-ferumoxytol contrast was assessed by difference of mean T2 * relaxation time pre-ferumoxytol and post-ferumoxytol contrast, in bone sarcoma subjects only.</description>
          <population>Only the participants with bone sarcomas were evaluated for this outcome.</population>
          <units>milliseconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.80" spread="2.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.27" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Differentiation of Lymphoma and Bone Sarcomas With Ferumoxytol-enhanced MRI</title>
        <description>Differentiation of lymphoma from bone sarcoma was assessed as the difference of mean T2 * relaxation time determined by ferumoxytol-enhanced MRI.
.</description>
        <time_frame>24 hours</time_frame>
        <population>The analysis population for this outcome includes the participants with bone sarcoma who participated in the pilot study.</population>
        <group_list>
          <group group_id="O1">
            <title>Mean T2 * Relaxation Time for Lymphoma Participants</title>
            <description>Participants with lymphoma evaluated with ferumoxytol-enhanced MRI</description>
          </group>
          <group group_id="O2">
            <title>Mean T2 * Relaxation Time for Bone Sarcoma Participants</title>
            <description>Participants with bone sarcoma, evaluated with ferumoxytol-enhanced MRI</description>
          </group>
        </group_list>
        <measure>
          <title>Differentiation of Lymphoma and Bone Sarcomas With Ferumoxytol-enhanced MRI</title>
          <description>Differentiation of lymphoma from bone sarcoma was assessed as the difference of mean T2 * relaxation time determined by ferumoxytol-enhanced MRI.
.</description>
          <population>The analysis population for this outcome includes the participants with bone sarcoma who participated in the pilot study.</population>
          <units>milliseconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.83" spread="1.03"/>
                    <measurement group_id="O2" value="7.71" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Differentiation of CD68-positive Tumor-associated Macrophages (TAM) in Lymphomas and Bone Sarcomas</title>
        <description>Differentiation of CD68-positive tumor-associated macrophages (TAM) between lymphoma and bone sarcoma was assessed as the difference of mean area density of CD68-positive TAM in those populations.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mean Area Density of CD-68-positive TAM in Lymphoma</title>
            <description>CD-68-positive tumor-associated macrophages (TAM) assessed in Lymphoma participants</description>
          </group>
          <group group_id="O2">
            <title>Mean Area Density of CD-68-positive TAM in Bone Sarcomas</title>
            <description>CD-68-positive Tumor associated macrophages(TAMs)in Bone Sarcomas participants</description>
          </group>
        </group_list>
        <measure>
          <title>Differentiation of CD68-positive Tumor-associated Macrophages (TAM) in Lymphomas and Bone Sarcomas</title>
          <description>Differentiation of CD68-positive tumor-associated macrophages (TAM) between lymphoma and bone sarcoma was assessed as the difference of mean area density of CD68-positive TAM in those populations.</description>
          <units>Percentage of CD68-positive TAM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="1.2"/>
                    <measurement group_id="O2" value="6.1" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Differentiation of CD163-positive Tumor-associated Macrophages (TAM) in Lymphomas and Bone Sarcomas</title>
        <description>Differentiation of CD163-positive tumor-associated macrophages (TAM) between lymphoma and bone sarcoma was assessed as the difference of mean area density of CD163-positive TAM in those populations.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mean Area Density of CD163-positive TAM in Lymphoma</title>
            <description>CD163-positive tumor-associated macrophages (TAM) was assessed in participants with lymphoma</description>
          </group>
          <group group_id="O2">
            <title>Mean Area Density of CD163-positive TAM in Bone Sarcoma</title>
            <description>CD163-positive tumor-associated macrophages (TAM) was assessed in participants with bone sarcomas</description>
          </group>
        </group_list>
        <measure>
          <title>Differentiation of CD163-positive Tumor-associated Macrophages (TAM) in Lymphomas and Bone Sarcomas</title>
          <description>Differentiation of CD163-positive tumor-associated macrophages (TAM) between lymphoma and bone sarcoma was assessed as the difference of mean area density of CD163-positive TAM in those populations.</description>
          <units>Percentage area of CD163-positive TAM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="1.5"/>
                    <measurement group_id="O2" value="9.4" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 hours</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Feraheme</title>
          <description>Intravenous injection of Feraheme, 5 mg Fe/kg
Feraheme: 5 mg Fe/kg iv
MR Scan: Standard of Care</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Heike Daldrup-Link</name_or_title>
      <organization>Stanford University</organization>
      <phone>650-723-8996</phone>
      <email>heiked@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

